High-performance neurostimulator

The lntellis™ with AdaptiveStim™ rechargeable neurostimulator is powered by proprietary Overdrive™ battery technology. It is designed to overcome limitations with other SCS systems and is optimized for the increased energy demands of High Dose (HD) therapy.

  • Smallest fully implantable spinal cord neurostimulator
  • <1 hour recharge — empty to full (approximate time)
  • Improved battery performance with minimal capacity fade (<5%)
  • Designed for patient comfort and more flexible placement during the implant
  • AdaptiveStim™ technology automatically adjusts the therapy as your patient moves, delivering a personalized treatment based on seven unique body positions.
  • Snapshot™ reporting, powered by AdaptiveStim™ technology, allows physicians to objectively monitor a patient's progress.
The Intellis product family for spinal cord stimulation

DTM™ SCS therapy

DTM™ SCS therapy is a proprietary therapy inspired by science and rooted in pre-clinical research, and adapted to provide superior clinical outcomes.

The DTM™ SCS 12-month RCT proved sustained superiority compared to conventional stimulation.

  • DTM™ SCS has an 84% back pain responder rate at 12-months.1
  • DTM™ SCS has a 69% profound back pain response rate (≥80% pain relief) at 12 months.1

Unmatched full-body MRI access

  • SureScan™ MRI technology allows MRI scans anywhere on the body enabling diagnostic care.*
  • Provide patients the same access as non-implanted patients* — now and in the future.
  • Shielded leads and proprietary device safeguards help patients safely get an MRI.*
  • Access matters — 98% of patients are expected to need at least 1 MRI within 10 years of implant.2

Creating new connections

The Medtronic adaptor extension creates a connection with certain Boston Scientific™ or Nevro™ leads. This enables patients with existing leads to gain access to superior DTM™ SCS therapy on Intellis™ INS.1 For patients wanting rapid recharge with Intellis™ INS or recharge-free convenience with Vanta™  INS, the adaptor extension allows you to offer meaningful pain relief with DTM™ SCS endurance therapy.3

Compatible products and features

Wireless External Neurostimulator

  • Wireless, sterile single-use external neurostimulator simplifies testing during trial and implant
  • Designed for patient comfort and convenience
Model Number 97725
Weight 71g (2.5oz)
Length 79mm (3.1in)
Width 74mm (2.9in)
Battery Type Non-rechargeable
Thickness 20mm (0.8in)
Front view of the Intellis wireless external neurostimulator

Clinician Programmer

  • Tablet with touchscreen interface
  • Secure, wireless programming outside the sterile field
  • Tailored programming workflows
  • Electronic transfer of a variety of reports
  • Bluetooth® communication
  • Requires the use of the Intellis™ clinician programmer app and communicator device
Clinician Programmer

Combined Patient Programmer and Recharger

  • Recharge from fully depleted battery
  • Easy-to-adjust therapy
  • Easy-to-read interface
  • Large, pliable recharge antenna designed for patient comfort
Combined Patient Programmer and Recharger

Compatible products

  • 1x8 Vectris™ and Vectris™ SureScan™ MRI percutaneous leads and INJEX™ anchoring system models 97791 and 97792
  • 16-electrode Specify™ SureScan™ MRI surgical leads

Intellis™ with AdaptiveStim™ technology

Model 97715
Channels 2
Volume 13.9cc
Height 57.1mm (2.2in)
Width 47.2mm (1.9in)

Manuals and technical guides

Access prescriber, implant, MRI, and other manuals on the Medtronic Manual Library. Search by the product name (Intellis™) or model number (97715). You may also call 800-961-9055 for a copy of a manual.

Contact us

U.S. clinician services


MR Safety Triangle Under specific conditions. Refer to product labeling for full list of conditions. Patients with non-Medtronic leads and an EMBSNV20 adaptor extension are not eligible for an MRI.

Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.


Fishman M, Cordner H, Justiz R, et al.  12-Month Results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021; 00: 1–12. doi: 10.1111/papr.13066.


Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531–537.


Peacock, Provenzano, Fishman, et al. A prospective multi-center study of a differential target multiplexed™ stimulation derivative in therapy-naive patients: Primary endpoint and 3-month outcomes. Poster presented at: North American Neuromodulation Society (NANS) annual meeting. Jan. 13–15, 2022.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.™